The systemic administration of oncolytic virus (OV) is often inefficient due to clearance of the
virus by host defense mechanism and spurious targeting of non-cancer tissues through the
bloodstream. Cell mediated OV delivery could hide the virus from host defenses and direct
them toward tumors: Mesencymal and neural stem cells have been described to possess
tumor-homing ability as well as the capacity to deliver OVs. In this review, we will focus on
approaches where OV and carrier cells are utilized for cancer therapy. Effective cellular …